Last reviewed · How we verify
Comparator: placebo, losartan, hydrochlorothiazide — Competitive Intelligence Brief
phase 3
Angiotensin II receptor blocker (ARB)
AT1 receptor (Angiotensin II type 1 receptor)
Cardiovascular
Small molecule
Live · refreshed every 30 min
Target snapshot
Comparator: placebo, losartan, hydrochlorothiazide (Comparator: placebo, losartan, hydrochlorothiazide) — Organon and Co. This drug is an angiotensin II receptor blocker (ARB) that lowers blood pressure by blocking the angiotensin II type 1 receptor, preventing vasoconstriction and aldosterone release.
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Comparator: placebo, losartan, hydrochlorothiazide TARGET | Comparator: placebo, losartan, hydrochlorothiazide | Organon and Co | phase 3 | Angiotensin II receptor blocker (ARB) | AT1 receptor (Angiotensin II type 1 receptor) | |
| placebo/valsartan | placebo/valsartan | Medical University of Silesia | marketed | Angiotensin II receptor blocker (ARB) | AT1 receptor (Angiotensin II type 1 receptor) | |
| Amosartan® tab | Amosartan® tab | Hanmi Pharmaceutical Company Limited | marketed | Angiotensin II receptor blocker (ARB) | AT1 receptor (angiotensin II type 1 receptor) | |
| Cozaar® | Cozaar® | Teva Pharmaceuticals USA | marketed | Angiotensin II receptor blocker (ARB) | AT1 receptor (angiotensin II type 1 receptor) | |
| Candemore tablet | Candemore tablet | Chong Kun Dang Pharmaceutical | marketed | Angiotensin II receptor blocker (ARB) | AT1 receptor (angiotensin II type 1 receptor) | |
| Valsartan (Diovan) | Valsartan (Diovan) | Radboud University Medical Center | marketed | Angiotensin II receptor blocker (ARB) | AT1 receptor (angiotensin II type 1 receptor) | |
| Irbesartan Oral Tablet | Irbesartan Oral Tablet | University of Southern Denmark | marketed | Angiotensin II receptor blocker (ARB) | AT1 receptor (Angiotensin II type 1 receptor) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Angiotensin II receptor blocker (ARB) class)
- Chong Kun Dang Pharmaceutical · 2 drugs in this class
- Baker Heart and Diabetes Institute · 2 drugs in this class
- Boryung Pharmaceutical Co., Ltd · 2 drugs in this class
- Lee's Pharmaceutical Limited · 2 drugs in this class
- Bristol-Myers Squibb · 1 drug in this class
- Guangdong Provincial People's Hospital · 1 drug in this class
- Fifth Affiliated Hospital, Sun Yat-Sen University · 1 drug in this class
- Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company · 1 drug in this class
- Bayer · 1 drug in this class
- Arbor Pharmaceuticals, Inc. · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Comparator: placebo, losartan, hydrochlorothiazide CI watch — RSS
- Comparator: placebo, losartan, hydrochlorothiazide CI watch — Atom
- Comparator: placebo, losartan, hydrochlorothiazide CI watch — JSON
- Comparator: placebo, losartan, hydrochlorothiazide alone — RSS
- Whole Angiotensin II receptor blocker (ARB) class — RSS
Cite this brief
Drug Landscape (2026). Comparator: placebo, losartan, hydrochlorothiazide — Competitive Intelligence Brief. https://druglandscape.com/ci/comparator-placebo-losartan-hydrochlorothiazide. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab